Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
4-13-2015 12:00 AM

TIMP3 Regulation of Macrophage Activation and Apoptosis
Michael S. Brock, The University of Western Ontario
Supervisor: Dr. Sean Gill, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Physiology and Pharmacology
© Michael S. Brock 2015

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Circulatory and Respiratory Physiology Commons, Medical Cell Biology Commons, and the
Medical Physiology Commons

Recommended Citation
Brock, Michael S., "TIMP3 Regulation of Macrophage Activation and Apoptosis" (2015). Electronic Thesis
and Dissertation Repository. 2740.
https://ir.lib.uwo.ca/etd/2740

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

TIMP3 REGULATION OF MACROPHAGE ACTIVATION AND APOPTOSIS

(Thesis format: Monograph)
By
Michael Brock
Graduate Program in Physiology and Pharmacology
A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Michael Brock 2015

Abstract
Acute respiratory distress syndrome (ARDS) is a lung disease involving profound
inflammation. Origins of persistent inflammation in select cases of ARDS are poorly
understood, and we propose persistent inflammatory macrophages may be one of its
mechanisms. Macrophages polarize to either promote inflammation, or suppress
inflammation. Tissue inhibitor of metalloproteinases 3 (TIMP3) reduces the proinflammatory polarization in macrophages. Additionally, studies have shown TIMP3
promotes apoptosis, and its absence delays recovery from bleomycin-induced lung injury.
We hypothesize that TIMP3 promotes apoptosis of murine macrophages through
inhibition of metalloproteinase activity and stabilization of FAS on the cell surface. Proinflammatory Timp3-/- bone marrow-derived macrophages (BMDMs) have significantly
higher metalloproteinase activity, and significantly lower sFASL-induced apoptosis
compared to WT BMDMs measured with FLICA and Annexin V. rTIMP3 treatment
rescued both metalloproteinase activity and apoptosis.
In conclusion, excessive metalloproteinase activity in Timp3-/- BMDMs is associated
with sFASL-induced apoptosis potentially due to metalloproteinase dependent death
receptor processing.
Keywords
TIMP3, macrophage, inflammation, BMDM, metalloproteinase, apoptosis, FAS, sFASL,
Annexin V, FLICA, TUNEL, ARDS, lung, MMP, ADAM
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Chapter 1.

Introduction

1.1 Overview
The healthy human lung is comprised of a multitude of cell types working to
promote oxygenation of the bloodstream from external atmospheric sources. During
inhalation the thoracic cavity expands generating a decrease in pleural pressures and
resulting in an influx of atmospheric gases into the lungs to equalize the resulting
pressure gradient [1]. The lungs consist of an intricate system of ever smaller branching
tubes leading to the smallest functional structure within the lungs, the alveolus [2]. An
alveolus is a spherical structure whose walls are a single cell thick and comprised of
epithelial cells [2]. These alveoli are enveloped by endothelial microvasculature
comprised of a meshwork of capillaries [2]. Capillaries support gas exchange between the
bloodstream and alveolus by way of bringing contained blood into close proximity of the
alveolar structure [3]. Oxygenation of the bloodstream requires oxygen molecules to
diffuse across two monolayers (epithelial and endothelial layers) in order to exit the
alveolus and enter bloodstream [2]. The binding of oxygen molecules to hemoglobin
(within red blood cells) allows for the transportation of oxygen within the bloodstream
[4]. Damage to this delicate microstructure, which occurs during acute respiratory
distress syndrome (ARDS), reduces the ability for adequate bloodstream oxygenation.
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1.2 Acute Respiratory Distress Syndrome
ARDS is characterized by lung inflammation, tissue damage, vascular
dysfunction and pulmonary edema, which collectively lead to impaired gas exchange and
hypoxemia [5]. The partial pressure of arterial oxygen (PaO2) divided by the fraction of
inspired oxygen (FiO2), which is referred to as the PaO2/FiO2 ratio, is indicative of the
efficiency of pulmonary gas exchange. For a patient to be diagnosed with ARDS,
bilateral opacities must be present on the chest radiograph in the absence of heart failure
and the PaO2/FiO2 ratio must be below 300 mmHg (lower PaO2/FiO2 ratios are
considered more severe cases of ARDS) [6]. ARDS can be caused by direct lung injury
from sources such as, bacterial infection, acid aspiration or near drowning experiences
[7]. Similarly, ARDS can have indirect causes, as seen following sepsis; the mechanism
of disease onset depends on the initial insult to the lung [7]. Ultimately, the varied
etiology and complex pathophysiology of ARDS, which are associated with a high
mortality rate, make designing preventative care therapies for ARDS patients difficult
resulting [8]. However, one commonality within ARDS pathophysiology, is the
generation of severe inflammation within the lungs following the initial injury [8].
The release of pro-inflammatory cytokines and chemokines from cells within
damaged pulmonary tissues leads to the recruitment of inflammatory cells, such as
neutrophils and macrophages to aid in the clearance of deleterious substances [9]. Acute
inflammation, however, can also cause loss of endothelial and epithelial barrier integrity,
resulting in an influx of proteinaceous edema fluid into the alveolar spaces [8]. In the

3

most serious cases of ARDS the inflammation progresses to the point of respiratory
failure, leading to severe hypoxemia and death [6]. The overall goal of the current
treatment strategy is to support patient oxygenation with mechanical ventilation while
allowing them to recover from the pulmonary injury [10].
Importantly, in some patients the severe inflammation persists beyond the normal
recovery timeline resulting in lack of resolution of symptoms and clinical features of
ARDS [11, 12]. Many studies have shown persistent inflammation can lead to worse
outcomes in ARDS [11–13], and that exhaled nitric oxide, which can be produced by
many inflammatory cells including macrophages, is a reasonable marker for persistent
lung inflammation [14].The mechanism of onset for this persistent inflammation in
ARDS, however, is currently unknown. Regulation of inflammation within the lung
tissues following injury is paramount, and through garnering a better understanding as to
how inflammation, particularly chronic inflammation is resolved, we will yield new
approaches to directly treat ARDS rather than simply providing supportive care.

1.2.1 ARDS and inflammation
Inflammation is a localized physical reaction to a sustained injury or infection that
causes fluid infiltration, cellular influx and swelling within a damaged tissue [15].
Inflammation within the lung environment is initiated by cells within the alveolus in an
attempt to rid the lung environment of deleterious substances or pathogens. Following an
insult to the lungs, an immune response is initiated, which is primarily driven by
macrophages within the lung [16]. Macrophages, which are resident to the alveolus,
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become activated and release multiple different cytokines and chemokines in order to
recruit additional inflammatory cells toward the site of injury [9]. Activation of resident
macrophages leads to the release of a multitude of cytokines including: interferon gamma
(IFNγ), tumor necrosis factor alpha (TNFα), and interleukin 1 beta (IL1β) [5]. The
release of these cytokines drives activation of nearby macrophages and epithelial cells in
a similar manner and promotes further influx of inflammatory cells, such as macrophages
and neutrophils to the site of injury [17]. These recruited macrophages will further
promote the inflammatory state to ensure all of the materials/pathogens that are injurious
to the tissue are engulfed and subsequently removed [17]. Following removal of the
hazardous materials or pathogens, resolution of inflammation occurs, which is required to
allow repair of the injured tissue [18].
Resolution of inflammation is generally associated with apoptosis and clearance
of infiltrated inflammatory cells, whose persistence could lead to prolonged inflammatory
symptoms [19]. Furthermore, failure to resolve inflammation despite removal or
resolution of the initial mechanism of injury could lead to enhanced tissue injury, as is
observed in a subset of patients following ARDS [11]. Importantly, this concept of
persistent non-resolving inflammation following lung injury can lead to increased tissue
damage, and one aim of this thesis is to uncover what underlying physiological processes
could achieve persistent non-resolving inflammation.
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1.3 Macrophages
Macrophages are immune system cells that specialize in the phagocytosis of
pathogens and deleterious substances, produce immune effector molecules, and typically
associate with sites of infection [20]. The macrophage is a terminally differentiated cell
type derived from monocyte precursors [21]. Monocytes becomes classified as
macrophages upon extravasation into target tissues; extravasation can be in response to
inflammatory signals, known as chemokines, or to generate resident macrophages within
the tissue [22]. Macrophages exist primarily as phagocytic cells engulfing particulate
matter in their nearby environment and relaying changes in their microenvironments to
other immune cells [23].
Macrophage subsets within the lungs include both resident and recruited
macrophages. The cells that permanently reside within the alveolar spaces (even in
healthy lungs) are termed resident macrophages, whereas macrophages drawn into the
lungs following injury are termed recruited macrophages [9]. These two populations
differ in their longevity as well as their intended function [24]. Resident macrophages are
long-lived cells necessary for relaying information to the immune system about their
surroundings, and play a key role in surfactant recycling [25]. The resident macrophage is
also involved in adaptive immunity through antigen presentation to helper T cells such
that appropriately targeted immune responses can be mounted within the lungs [26].
Resident macrophage activation causes release of many pro-inflammatory cytokines that
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recruit additional neutrophils and macrophages to the site of injury in order to subdue the
threat by engulfment and eventual clearance [17, 27].
Monocytes from the bone marrow travel toward the site of injury through the
vasculature and upon reaching the site of the injury, will extravasate into the tissue at the
area of increased cytokine and chemokine levels [21]. Within the lungs, after monocytes
enter the pulmonary capillary bed, they will migrate through the endothelial monolayer,
pass through the interstitial space, and migrate across the epithelial barrier [9]. It is at this
point, once contained with the injured tissues, that monocytes become classified as
recruited macrophages. Recruited macrophages are best described as cells derived from
monocytes that have translocated into a tissue in order to carry out an immunomodulatory
function at a specific location where infection and/or tissue injury has occured [23]. Once
the macrophage arrives at the site of injury, a drastic alteration to their gene expression
occurs allowing for the appropriate response to the local tissue microenvironment – a
process termed macrophage polarization [28].

1.3.1 Macrophage polarization
Macrophage polarization is a macrophage-specific cellular activation process that
causes a shift in the expression of multiple genes in response to the presence of
inflammatory signaling molecules within their local tissue microenvironment [29].
Environmental cues, such as bacterial products, or pro- and anti-inflammatory cytokines
drive this change in gene expression thereby enabling the macrophage to carry out
specific immune functions [28]. Two distinct and opposite ‘polarizations’ exist in
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macrophages, including the pro-inflammatory, classically activated (M1-polarized)
macrophage, and the anti-inflammatory, alternatively activated (M2-polarized)
macrophage [28].
One of the primary functions of M1-polarized (pro-inflammatory) macrophages is
to promote the immune response in order to sufficiently deal with an injury/infection
within a specific tissue. In the overall disease process, however, the inflammatory
response must subside in order to promote the recovery of damaged tissues back to a
healthy state. The cessation of inflammation is in-part due to a second role of
macrophages. The function of M2-polarized macrophages is to support the resolution of
inflammation, primarily through secretion of multiple anti-inflammatory cytokines such
as, interleukin 1 receptor antagonist (IL1ra), interleukin 10 (IL10), and transforming
growth factor beta (TGFβ) [9, 30]. Though macrophages directly clear foreign materials,
pathogens, and debris by phagocytosis, they are also carry out efferocytosis, the act of
engulfment of apoptotic cells [31]. By engulfing apoptotic cells, macrophages protect
their environment from the pro-inflammatory internal contents of neutrophils and other
macrophages, which would be released following disruption of cell membranes [32].
Ultimately, macrophage activity within an injured tissue reflects the injury repair
process. The initial role of the macrophage is to promote inflammation in order to clear
the pathogen and prevent systemic inflammation [9]. Once the initial insult/injury is
cleared, there is a shift in the activity of macrophages towards promoting the resolution
of the inflammation and repair of the damaged tissue [33]. Importantly, if the M1-
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polarized (pro-inflammatory) macrophage persists, this may result in an aberrant proinflammatory environment and subsequently lead toward chronic tissue damage [11].
Based on this concept, work within this thesis specifically focuses upon the M1-polarized
state of macrophages, as the main focus is to identify if ARDS-associated persistent
inflammation is brought about by persistent, pro-inflammatory macrophages.

1.3.2 Macrophage Apoptosis
Apoptosis, or programmed cell death, is a process utilized within living systems
in order to clear or remove cells that are no longer required, or are damaged beyond
repair, and to ensure they do not spill their contents into their environment causing
damage to surrounding cells [34]. One mechanism for removal of apoptotic cells is
efferocytosis, the engulfment of apoptotic bodies by phagocytic cells [34]. Efferocytosis
relies on the presence of cell surface proteins, or “eat-me” signals to identify appropriate
targets [35]. One example of an eat-me signal is phosphatidylserine, which is found on
the inner leaflet of the cell membrane of healthy cells but accumulates on the surface of
apoptotic cells [35, 36]. Apoptosis is a highly controlled and regulated cascade that
begins with an event, such as damage to the cell or a signalling molecule, which triggers
the initiation of apoptotic machinery.
One major group of surface proteins that initiate apoptosis following interaction
with an extracellular ligand are the ‘tumor necrosis factor (TNF) receptor
superfamily’[37]. Members of this family include the receptors TNFR1, TNFR2 and
FAS, with prominent ligands including, TNFα, soluble FAS ligand (sFASL), and TRAIL
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[37]. FAS is capable of triggering apoptosis by binding to sFASL (Figure 1-1) [38].
sFASL binding to FAS leads to trimerization of similarly bound receptor-ligand
complexes (Figure 1-1)[37]. Following trimerization, FAS receptors associate with the
FAS activated death-domain (FADD), which in turn binds to and activates pro-caspase-8
(Figure 1-1)[39].
Caspases, which are cysteine-dependent aspartate-directed proteases, are internal
cell signalling proteins with many known functions, including the proteolytic processing
of proteins associated with the apoptotic cascade [40]. Twelve caspases exist in humans
and most can be divided into two primary groups. These groups include the initiator
caspases (2, 8, 9 and 10), which start the apoptotic cascade, and the executioner caspases
(3, 6 and 7), which once activated, lead to irreversible apoptosis [41, 42]. Within the FAS
apoptotic cascade, caspase 8 (an initiator caspase) will activate caspase 3 (an executioner
caspase) to cause apoptosis [43]. Apoptosis is thought to reduce inflammation within the
lungs via clearance of pro-inflammatory macrophages. This concept is supported by
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Figure 1-1: sFASL/FAS ligand-receptor induced apoptosis.
(1) sFASL binds to its receptor FAS at the cell surface (2). This interaction leads to
trimerization of bound receptor-ligand complexes (3), which promotes the recruitment of
the FAS activated death domain (FADD) [38]. The FADD-FAS timer complex recruits
Procaspase 8 (4) and subsequently complexes with it (5) [44]. The pro-domain on
Procaspase 8 is cleaved (6) and active Caspase 8 is released within the cell to activate
downstream executioner caspase 3 (7) and ultimately lead to apoptosis [38].
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pro-inflammatory macrophage apoptosis being associated with decreased neutrophil
recruitment in pneumonia, coupled to a decrease in the probability of mice becoming
bacteremic [18]. An inability of apoptotic machinery to function properly could lead to
persistence of M1-polarized (pro-inflammatory) macrophages, ultimately promoting a
persistent inflammatory environment within tissues. Apoptosis and subsequent clearance
of macrophages is a mechanism capable of invoking inflammatory suppression, and if
unbalanced, could be the root of a persistent inflammatory phenotype in some patients
[19]. This thesis aims to study the repair of lung injury, and as macrophages are key
mediators of inflammation, and its resolution, they will be a key focal point within this
study.

1.4 Metalloproteinases
Metalloproteinases are a group of enzymes whose function is to degrade and
process biologically relevant proteins within the extracellular environment [45]. While
there are many different families of metalloproteinases, this study focused on two of
those families. First, the matrix metalloproteinases (MMPs) are a family of 24 zincdependent endopeptidases with the capability of degrading many extracellular and
membrane bound proteins [46]. MMPs were classically thought to primarily degrade the
extracellular matrix (ECM); however, a more thorough understanding of the function of
these complex enzymes has led to a refined definition relating their activity to processing
biologically active components within the extracellular environment [47]. This
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processing includes but is not limited to, growth factor activation, chemokine processing,
cell surface protein cleavage, and remodeling of the ECM [45].
The second metalloproteinase family of interest are the ‘a disintegrin and
metalloproteinases’ (ADAMs) family, which differ from most MMPs by way of a
transmembrane region and a disintegrin domain [48]. ADAMs differ functionally from
MMPs as ADAMs are predominantly thought to be “sheddases” and are involved in
ectodomain shedding of cell surface proteins and receptors [49]. One well categorized
metalloproteinase with sheddase activity is ADAM17, which has been shown to cleave
TNFα and its receptor from the cellular surface [50]. Most MMPs and ADAMs are
produced as zymogens, and only become active once released from their pro-domain
[51]. Metalloproteinases, as their name implies, require interaction of a metal ion
(typically zinc) with the catalytic domain for functional activity [45]. Importantly,
metalloproteinase activity is regulated at multiple levels including regulation at the level
of expression as well as by tissue specific inhibitors [52].

1.4.1 Metalloproteinases in ARDS
Metalloproteinases, based on their ability to process pro-inflammatory cytokines,
are known to mediate inflammatory processes within ARDS [47]. Previous publications
have categorized the most prevalent metalloproteinases in ARDS [53]. Lavage fluids
from subjects with ARDS have elevated levels of MMP1, -2, -3, -8, -9, and -13 [54]. It
has been proposed that MMP8 and MMP13 possess anti-inflammatory properties in
ARDS, mediated through inactivation of macrophage inflammatory protein-1ߙ and
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monocyte chemoattractant protein-1, respectively [55, 56]. Conversely, lavage fluid
levels of MMP1 and MMP3 have been correlated with elevated mortality rates in ARDS,
suggesting that they play a more deleterious role in ARDS [57]. A previous publication
has shown ADAM17 to be capable of ectodomain shedding of TNFα and its receptors,
which is a key inflammatory signalling molecule and thus associated with ARDS [50].
Based on their regulatory control of inflammation within ARDS, metalloproteinases will
be a primary interest for our study of inflammation resolution. Macrophage function
relies upon the ability of the macrophage to respond to external stimuli within the tissue
microenvironment, and previously acquired data suggests that metalloproteinases are
capable of regulating macrophage response to external signaling molecules [29].

1.4.2 Metalloproteinases in Macrophage Function
MMPs and ADAMs can produce pro- and anti-inflammatory effects and are
produced by macrophages in both polarized states; however, these metalloproteinases are
differentially expressed depending on the activated state of the macrophage [58]. For
example, the expression of MMP1, -3, -7, -10, -12, and -14 is elevated in M1-polarized
macrophages, whereas expression of MMP2, -8 and -19 is decreased and MMP11, -12,
and -25 is increased in M2-polarized macrophages [58]. Furthermore, ADAM9, -15, and 17 have also been shown to be expressed by macrophages in pro-inflammatory settings of
atherosclerotic plaques [59, 60]. Metalloproteinases can also directly modulate
macrophage function. For example, MMP2 has been shown to cleave CC-chemokine
ligand 7, a chemotactic protein known to induce macrophage infiltration, rendering it

14

inactive, and potentially decreasing the levels of pro-inflammatory macrophages recruited
to the site of injury [61]. Second, MMP28 has been shown to have high expression within
the mouse lung, where it is capable of reducing macrophage recruitment and polarizing
macrophages towards an M2-polarization within a pulmonary fibrosis injury model [62,
63]. Thus, macrophages can promote or restrict inflammation based on their polarization
and this polarization is regulated by environmental cues. These cues, namely cytokines,
can be processed by metalloproteinases suggesting that metalloproteinases, which are
expressed by macrophages, may have an important role in regulating macrophage
response to environmental cues and consequently, the inflammatory environment
following injury.

1.4.3 Metalloproteinases and Apoptosis
Persistent non-resolving inflammation in select cases of ARDS could be due
aberrant apoptosis within the pro-inflammatory macrophage. Metalloproteinases have
been shown to play a role in the processing of cellular surface receptors, and importantly,
some of these receptors are involved in apoptotic signaling cascades [50, 64]. FAS, one
such receptor, can cause apoptosis in macrophages [65]. Previous studies on hepatocytes
has led to a direct correlation between apoptosis of hepatocytes and the shedding of the
FAS ectodomain [66]. Furthermore, in hepatocytes ADAM17 has been shown to cleave
members of the TNF superfamily restricting the activation of cell death signaling
pathways [67]. ADAM17 activity is regulated by tissue inhibitor of metalloproteinases 3
(TIMP3) [68]. In the absence of TIMP3, ADAM17 activity is elevated, FAS ectodomain
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shedding is increased, and hepatocytes are protected from undergoing cell death [67].
Unabated metalloproteinase-associated receptor shedding might render cells unable to
properly respond to extracellular signaling that typically would induce an apoptotic
cascade [50].

1.5 Tissue inhibitors of metalloproteinases
The TIMP family of metalloproteinase inhibitors is comprised of four distinct
family members, TIMP1, -2, -3, and -4 [45]. Each TIMP can inhibit metalloproteinases,
though their specificity and ability to act in certain environments varies [52]. TIMPs have
been studied thoroughly within the context of wound healing, and are thought to have a
key role in regulating the ability of metalloproteinases to enable tissue repair and
remodeling, as well as inflammatory processes [45]. TIMPs inhibit metalloproteinases
through binding to the active site on the metalloproteinase; this association inhibits the
catalytic activity of metalloproteinases [69].
Past studies have shown that TIMP3 is the only TIMP to associate with the ECM
[70]. Specifically, TIMP3 is known to be localized to sulphated proteoglycans within the
ECM [71]. TIMP3 can be produced by multiple different cell types within the lungs,
including endothelial cells, fibroblasts and macrophages [72, 73]. TIMP3 regulates
multiple metalloproteinases and without sufficient TIMP3, the activity of these proteases,
such as ADAM17, becomes increased, which in-turn leads to increased shedding of
multiple cell surface receptors [67].
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1.5.1 TIMP3 and ARDS
Timp3-/- mouse lung morphology is altered from wild type (WT) animals; Timp3-/mice develop enlarged alveolar spaces, and die prematurely beginning at 13 months of
age implicating TIMP3 as an important protein within the lung [74]. Additionally,
following both bleomycin-induced and lipopolysaccharide (LPS)-induced lung injury,
mice lacking TIMP3 recovered more slowly than the WT animals [72, 75]. Intensified
Timp3-/- lung inflammation and hindered recovery were demonstrated by greater
inflammatory cell presence within bronchoalveolar lavage (BAL), and through decreased
markers of inflammatory resolution within BAL fluids from Timp3-/- mice vs. WT mice
[72, 75]. Furthermore, BAL fluid from the Timp3-/- lungs induced greater neutrophil
chemotaxis compared to WT lavage fluids in culture suggesting that the persistent
neutrophil accumulation in Timp3-/- mice was due to ongoing neutrophil influx [75]. In
addition, Timp3-/- mice have enhanced lung compliance at baseline, which is made worse
following sepsis [76, 77] As well, these alterations following sepsis appear to be due to
macrophages, as when macrophages were depleted, mice were protected from alterations
in lung mechanics brought about by sepsis [77]. These examples of lung dysfunction
following injury in Timp3-/- lungs mimic the issues of persistent inflammation following
ARDS, and also suggest that TIMP3 plays an important role in lung injury repair. Thus,
TIMP3 regulates inflammation and repair through control of metalloproteinase activity,
and based on this role, it will be a principal protein of interest in regards to this thesis.
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1.5.2 TIMP3 and Macrophage function
Loss of TIMP3 from the lung results in dysfunctional repair and resolution of
inflammation following injury. Macrophages, which are known to express TIMP3, are
known to be key mediators of both the initiation and resolution of inflammation as well
as tissue repair following lung injury [9, 78]. Timp3-/- bone marrow-derived macrophages
(BMDMs) appear to be genetically and functionally different than WT BMDMs [72].
Following LPS treatment (an M1 polarizing stimulus), BMDMs from Timp3-/- mice
exhibited increased pro-inflammatory gene expression compared to similarly polarized
WT BMDMs. This elevated pro-inflammatory gene expression levels in Timp3-/BMDMs was rescued when BMDMs were treated with recombinant TIMP3 (rTIMP3)
[72]. Furthermore, Timp3-/- BMDMs also induced significantly more neutrophil
chemotaxis in vitro and appeared resistant to apoptosis compared to WT BMDMs [72].
Timp3-/- macrophages were also found to release more TNFα than their WT
counterparts due to increased ADAM17 activity, which promoted a more proinflammatory environment suggested by increased IL6 levels in serum [78]. Interestingly,
overexpression of TIMP3 in macrophages had the opposite effect; a decrease in the
mRNA levels of multiple pro-inflammatory genes was observed within fatty tissue in
mice on a high fat diet [79]. Together, this data suggests that TIMP3 has an important
role regulating macrophage function and response to environmental cues. As ADAM17 is
known to target members of the TNF superfamily, lack of ADAM17 inhibition by TIMP3
could modify macrophage function leading to macrophage persistence and subsequent
non-resolving lung inflammation.

18

1.5.3 TIMP3 and Apoptosis
There are many studies that lend support toward TIMP3 acting as a pro-apoptotic
protein. For example, overexpression of TIMP3 causes increased levels of apoptosis
within multiple different cells lines [80]. Adenoviral expression of TIMP3 in melanoma
cells, leads to a marked increase in the levels of FAS, TNFR1 and Caspase 3 detected via
immunostaining (Figure 1-2) [81]. TIMP3 overexpression has also shown to be able to
induce elevated levels of apoptosis within smooth muscles cells from rat aortic tissues
[82]. Additionally, macrophages lacking TIMP3 appear to be resistant to both
staurosporine and sFASL-induced apoptosis, which further supports a role for TIMP3 in
the control of apoptosis [72]. Importantly, use of a mutant TIMP3 with abolished MMP
inhibitory function no longer had a pro-apoptotic function, linking the ability for TIMP3
to promote apoptosis to an MMP-dependent mechanism [83]. Based on previous studies
TIMP3 has been shown to promote apoptosis in multiple different cell models, and
coupled to its anti-inflammatory role in the lungs, it is a key focus for study within this
thesis.
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Figure 1-2: Proposed model of TIMP3 mediated macrophage apoptosis.
(A) TIMP3 has been shown in previous studies to stabilize pro-apoptotic receptors,
known as death receptors, on the cell surface through its ability to inhibit
metalloproteinase activity [67, 80, 81, 83]. Stabilized death receptors on the cell surface
allow for ligand-receptor interaction at the cell surface and promote activation of a proapoptotic signaling cascade [84]. (B) Deregulated metalloproteinase activity (i.e. in the
absence of TIMP3) leads to enhanced shedding of the death receptors (e.g. FAS) leading
to desensitization to apoptotic stimuli [72]. Apoptosis within the pro-inflammatory
macrophage is a major contributing factor to the overall cessation of inflammation in
wound healing [19]. Thus, TIMP3 may have a key role in regulating the ability of
macrophages to undergo apoptosis (A), and a loss of TIMP3 may result in macrophages
that are resistant to undergoing apoptosis (B). Importantly, failure of M1-polarized
macrophages to undergo apoptosis could allow these macrophages to persist within the
damaged tissue following injury, ultimately resulting in ongoing, chronic inflammation.
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1.6 Rationale:
1) Persistent or chronic inflammation following lung injury can lead to increased tissue
damage.
2) Macrophages are key mediators of both the initiation and resolution of inflammation.
3) TIMP3 has a role in regulating inflammation through control of metalloproteinase
activity.
4) TIMP3 is expressed in the lung by multiple cells types, including macrophages.
5) Mice lacking TIMP3 have impaired resolution of inflammation following lung injury,
possibly due to altered macrophage polarization and apoptosis.
It is known that mice lacking TIMP3 have a more inflammatory lung environment
following lung injury [75] . The macrophages within the Timp3-/- lungs likely are
promoting greater inflammation as supported by the increased pro-inflammatory gene
expression observed in Timp3-/- BMDMs [72]. Timp3-/- murine lungs have increased
metalloproteinase activity levels [74, 75, 85] and TIMP3 is known to stabilize death
receptors at the cell membrane [67, 80, 81, 83]. Together, this data suggests a potential
mechanism of apoptotic resistance for the M1 macrophage population within the lungs of
the Timp3-/- mice. Specifically, persistent inflammation in Timp3-/- lungs following injury
would be the result of the sustained presence of inflammatory macrophages in the
alveolar spaces due to increased metalloproteinase activity leading to shedding and
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desensitization of death receptors on the cell surface of M1-polarized Timp3-/macrophages. However, if shedding of death receptors occurs within the alveolar
macrophage and whether this shedding of death receptors from macrophages would drive
the persistent inflammation following ARDS is not yet known. This thesis proposes to
study a potential mechanism for the persistent inflammation associated with ARDS, and
potentially answer how this poorly understood complication could arise.

1.7 Hypothesis
We hypothesize that TIMP3 promotes apoptosis of murine macrophages through
inhibition of metalloproteinase activity and the stabilization of FAS on the cell surface.

1.8 Objectives:
1)

Establish and characterize WT and Timp3-/- bone marrow-derived macrophage
(BMDM) cultures.

2)

Identify the mechanism through which TIMP3 regulates macrophage apoptosis.
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Chapter 2.

Methods

2.1 BMDM Isolation and Culture
BMDMs were isolated and cultured from the bone marrow of WT and Timp3-/mice using techniques previously found to produce a pure population of macrophages
[57, 67]. Mice between the ages of 8 and 12 weeks were euthanized via pentobarbital
sodium overdose (Euthanyl forte, Bimedia-MTC; ethics approval #Mehta2011-026).
Following sacrifice, the tibia and femur from the hind legs of the animal were isolated by
blunt dissection and placed into cold 15 mM EDTA/PBS (pH 7.4). The proximal and
distal ends of the bones were removed and the bones placed into separate 500 µL
Eppendorf tubes that had been punctured through the bottom with an 18.5 gauge needle.
The 500 µL tubes were nested within 1.5 mL Eppendorf tubes and the tubes spun at 2000
RCF for 1 minute at 4 °C. The isolated marrow within the 1.5 mL Eppendorf tube was
then resuspended in 1 mL of 15 mM EDTA/PBS and marrow from the same animal was
combined in a 15 mL falcon tube. Cells were centrifuged at 400 RCF for 10 minutes at 4
°C and the supernatant discarded. The cell pellet was resuspended in 1 mL of red blood
cell (RBC) lysis buffer (eBioscience, Catalogue #00-4333-57) and placed on ice for 4
minutes, after which, 5 mL of PBS was added to the cell suspension. The suspension was
then centrifuged at 400 RCF for 10 minutes at 4 °C and the supernatant removed. This
cell pellet was then resuspended in 8 mL macrophage media (RPMI 1640, 30% L929 cell
supernatant [refer to 2.1.1], 10% FBS, 2mM L-glutamine, 100 I.U. /mL penicillin, and
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100µg/mL streptomycin), plated onto a 100 mm tissue culture treated plate, and placed at
37 °C for 24 h.
After 24 h, the conditioned media from each of the 100 mm plates was collected
and each plate was rinsed with 5 mL sterile PBS to collect non-adherent and loosely
adherent cells. The conditioned media and PBS rinse were placed into a sterile 15 mL
falcon tube and centrifuged at 400 RCF for 10 minutes at 4 °C. The supernatant was
removed, the cell pellet resuspended in 8 mL macrophage media, and the cells plated on a
150 mm sterile non-tissue culture treated plates containing an additional 12 mL
macrophage media. These 150 mm plates were then cultured at 37 °C for 6 additional
days.

2.1.1 L929 cell culture
In order to differentiate bone marrow isolate into BMDMs, culture media requires the
presence of macrophage-colony stimulating factor (M-CSF). Conditioned media from L929 cell cultures (ATCC, Catalogue # CCL-1), which contains high concentrations of MCSF, is well documented as an inexpensive source of M-CSF for use in BMDM cell
culture [86]. To produce adequate concentrations of M-CSF, 4.4 X 106 L-929 cells were
plated on 150 mm tissue culture treated plates and grown in 30 mL of IMDM media
containing 10% FBS, 100 I.U./mL penicillin and 100 µg/mL streptomycin. Cells were
grown for 14 days after which the conditioned media (i.e. L-929 cell supernatant) was
collected, passed through a sterile 20 µm filter and stored at -80 °C until use.
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2.1.2 BMDM Polarization
After 1 week of growth, the conditioned media was collected, used to rinse the
plate once, and then placed in a 50 mL falcon tube on ice. 20 mL of cold PBS was then
added to the plate and the plate placed at 4 °C for 30 minutes. Cells were then lifted by
gently washing the plate with the chilled PBS. This suspension was then added into the
50 mL falcon tube with the conditioned media and the sample was spun at 400 RCF for
10 minutes at 4 °C. The supernatant was aspirated and the macrophages resuspended in 1
mL macrophage media. The number of macrophages was then determined via
haemocytometer and the macrophage concentration diluted to 2 x 106 cells/mL.
Macrophages were then plated into 6- or 24-well plates at 2 x 106 and 4 x 105,
respectively, and allowed to grow for 24 h at 37 °C. After 24h, media was removed from
the cells and replaced with new media lacking M-CSF (i.e. without L-929 cell
supernatant), referred to as stimulation media (RPMI 1640, 10% FBS, 2mM L-glutamine,
100 I.U./mL penicillin, and 100µg/mL streptomycin). Stimulation media also included
either LPS (E.Coli-0111LB4; 100 ng/mL; Sigma-Aldrich, Catalogue #L-2630-100mg) or
PBS to drive the cells toward an M1-polarized or unpolarized (M0) phenotype
respectively. BMDMs were stimulated with stimulation media over 24 h to allow for
macrophage polarization to occur, a method supported by previous studies [72]. A subset
of macrophages was also incubated in the presence/absence of human recombinant
TIMP3 (rTIMP3; 1µg/mL) during the 24h polarization.

26

2.2 Conditioned media and protein/RNA isolation
BMDMs (2 x106 cells per well) were plated onto tissue culture treated 6-well
plates and polarized as described above [2.1.2]. Following polarization, the conditioned
media was removed and aliquoted into 1.5 mL Eppendorf tubes before being stored at -80
°C for later use. Cells were then rinsed with PBS prior to protein isolation. To isolate
protein, 200µL of Sigma CelLyticTM M Cell Lysis Regent was added to each well
(Sigma-Aldrich, Oakville, ON; C2978-50ML) and the cells left on ice for 20 minutes.
After 20 minutes, wells were scraped and cell lysate collected and placed in Eppendorf
tubes on ice. Samples were further sonicated for 20 seconds at 60% amplitude and spun
down at 20 000 RCF for 15 minutes to ensure insoluble debris was not collected in our
protein samples. Following sonication, samples were stored at -80°C.
RNA was isolated using the RNeasy kit (Qiagen; Cat. #74104). Briefly, 200 µL
RLT buffer containing 2 µL beta-mercaptoethanol was added to each well. Wells were
then scraped, and cell lysate collected and placed in Qiashredder tubes (Qiagen; Cat.
#79656). Samples were spun at 10 000 x g for 30 seconds. Flow through was collected
from the Qiashredder tubes, placed into RNeasy spin columns, washed with a series of
buffers, and the RNA eluted from the columns by water, as per the manufacturer
instructions.
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2.2.1 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Purity (230/260 and 260/280 ratios) and concentration of isolated RNA was
determined by analysis with the NanoDrop 1000 spectrophotometer (Thermo, Waltham,
MA, USA). Isolated RNA (2 ug) was then reverse transcribed by using a High capacity
cDNA reverse transcription kit (Invitrogen 43368814 ABI) according to manufacturer’s
instructions. Il12b and Nos2 gene expression was then analyzed using TaqMan Gene
Expression Assays from Applied Biosystems (Invitrogen, Grand Island, NY, USA; Il12,
Cat. # 4331182; Nos2, Cat. # Mm00440502_m1) and the CFX96 Real Time System
(BioRad, Philadelphia, PA, USA). Hypoxanthine-guanine phosphoribosyltransferase
(Hprt), a housekeeping gene, was used to normalize expression of genes of interest. qRTPCR generated the cycle threshold (Ct) value for each gene and this value was then used
to determine gene expression relative to WT unpolarized BMDMs. For this analysis, ∆Ct
was the normalization of a given gene to Hprt within a specific sample (i.e. WT M1polarized BMDMs), ∆∆Ct was the normalization of a specific sample (i.e. WT M1polarized BMDMs) to the control sample (WT unpolarized BMDMs), and the relative
quantity (RQ) was the fold change in expression of a specific sample (i.e. WT M1polarized BMDMs) relative to the control sample (WT unpolarized BMDMs). RQ was
determined by the following equation: RQ = 2-∆∆Ct.

2.2.2 OmniMMP assay
Total metalloproteinase activity in conditioned media and cell lysates was
determined through use of the OmniMMP Assay, a broad-spectrum, fluorescent assay.
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Lysate and conditioned media analyses were conducted with the use of a Victor 3 plate
reader (PerkinElmer, Woodbridge, ON). Equal volumes of sample were loaded in each
well and prior to adding the active fluorescent substrate (P126), baseline levels of
fluorescence were measured for each sample. Following the addition of P126
(Excitation/Emission – 328 nm/393 nm), samples were compared to values of positive
controls, wells containing P127 (the fluorescent conjugate generated from cleavage of
P126; Excitation/Emission – 328 nm/393). Measures of activity in a given sample were
taken after 1, 3, 5, 10, 15, 30 and 60 minutes. Following the initial hour of the
experiment, further measurements were taken after 2, 3, 4, 8, 22, 24, 32, 46 and 48 h.
Data was subsequently analyzed through overall time course plots, area under the curve
calculations, as well as single time point assessments.

2.3 Assessment of macrophage apoptosis
2.3.1 FLICA Staining
Differentiated BMDMs were plated onto 48-well tissue culture plates (2 x 105
cells per well) and after 24 h, were polarized toward an M1-polarization or left
unpolarized as described above (2.1.1 and 2.1.3). BMDMs were then stimulated with
sFASL (100ng/mL; SuperFasLigand, Enzo Life Sciences, Address; ALX-522-020-3005)
for 2, 4, and 8 h. Following induction of apoptosis with sFASL, caspase activation was
assessed with the FLICA caspase assay as per the manufacturer’s instructions
(ImmunoChemistry Technologies). For these studies, FLICA is resuspended in DMSO
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(50 µL DMSO/vial) and this DMSO/FLICA mixture is then further diluted in PBS (1:4
FLICA/DMSO to PBS). For the last hour of the sFASL stimulation period, the diluted
FLICA reagent or DMSO/PBS alone was added directly into the well (3.3µL/100µL
media), the plates gently agitated to ensure even dispersal of the FLICA reagent, and the
plates placed back at 37°C. Following stimulation, the plates were removed from the
incubator, the media aspirated, and the wells washed with PBS before 200 µL of 10%
formalin was added to each well to fix the cells. After 45 min of fixation at room
temperature, the formalin was aspirated and wells were once again washed with PBS.
Hoechst’s stain (Hoechst 33342; Invitrogen, Catalogue #H3570) was used in order to
fluorescently label the nuclei of the BMDMs. Plates were then imaged using fluorescent
microscopy (FLICA excitation/ emission: 550 nm/590-600 nm; Hoechst
excitation/emission: 361 nm/486 nm) the number of Hoechst positive cells per field of
view were counted through the use of a macro in ImageJ. Automated counts of the
number of FLICA positive cells were confirmed by two blinded reviewers.

2.3.2 TUNEL Staining
Differentiated BMDMs were plated onto glass coverslips contained within 24well plates (4 x 105 cells per well) and after 24h, were polarized toward the M1polarization or left unpolarized as described above (2.1.1 and 2.1.3). Apoptosis was
induced via stimulation with sFASL for 2, 4 and 8h after which, cells were fixed in 10 %
formalin for 30 minutes at room temperature, and then washed repeatedly with PBS.
Fixed BMDMs were then permeabilized with a 1 % Na+ citrate and 0.1 % triton X-100
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solution for 150 seconds at 4°C and the endogenous peroxidase activity was quenched by
treatment with 3% H2O2 in 50% methanol for 30 minutes at room temperature. Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was then
performed according to the manufacturer’s instructions to assess DNA fragmentation
(Roche, Catalogue #11-684-817-910). Briefly, diluted TUNEL enzyme was added into
each well and incubated in darkness for 1 hour at 37°C. Wells containing glass coverslips
were washed with PBS and 50 µL of POD converter solution was added to each well for
30 minutes at 37°C. Prior to imaging the slides, 50 µL of DAB chromagen solution was
added to each well. The DAB solution was incubated for between 1-5 minutes, during
which the reaction was monitored under the microscope to ensure development was not
excessive. The developer was then quenched by dilution with PBS and slides were
viewed under a visible light microscope. The total number of cells and the number of
TUNEL positive cells per field of view were counted by blinded reviewers due to
automation errors.

2.3.3 Annexin V Staining
BMDMs were differentiated, replated at 2 x 106 cells per well in a 6-well nontissue culture treated plate, and after 24 h, left unpolarized or driven toward M1polarization as described above (2.1.1 and 2.1.3). Following polarization BMDMs were
stimulated with either PBS or sFASL (100 ng/mL) for 1 and 2 h to induce apoptosis. At
the end of stimulation the 6-well plates were centrifuged at 200 RCF for 5 minutes at
4°C, media was removed, and BMDMs were washed with PBS. BMDMs were then
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treated with 0.5 mM EDTA/PBS at 37°C for 5 minutes to gently lift from the plate after
which, collected BMDMs were pipetted into a U-bottomed 96 well plate and centrifuged
at 200 RCF for 5 minutes at 4°C. EDTA/PBS was aspirated from the wells and replaced
with 100 µL of Annexin V binding buffer (0.1 M HEPES, pH 7.4; 1.4 M NaCl; 25 mM
CaCl2). Annexin V and propidium iodide (PI; 2 uL of each) were added into the wells for
10 minutes in darkness at room temperature. Once stained, an additional 150 µL of
Annexin V binding buffer was added to each well. The presence of Annexin V and PI in
each of the cell populations was then analyzed by flow cytometry in the Guava-12HT
flow cytometer (Millipore, Billerica, MA, USA). Annexin V+/PI- cells were considered
apoptotic cells, whereas Annexin V+/PI+ cells were considered dead cells and Annexin V/PI- cells were considered live cells.

2.4 Western Blot
Total protein concentration of BMDM cell lysates was determined by Bradford
assay. Once concentrations were calculated, 40 µg of total protein from each sample was
heated to 100°C in the presence of β-Mercaptoethanol, loaded on a 4-15 % gradient mini
gel (Biorad, Catalogue #J00094) with PageRuler Plus protein ladder loaded (Thermo
Fisher Scientific, Catalogue #G00203) in Tris-Glycine SDS Running buffer (25mM Tris,
192 mM Glycine, 0.1 % SDS, pH 8.3), and run at 100 V for 60 minutes. Separated
proteins were then transferred to a PVDF membrane over the course of 60 minutes at 100
V in transfer buffer containing 20 % methanol. Blots were then rinsed in PBS, blocked in
PBS with 3 % BSA for 1 h, and probed with rabbit-anti-mouse FAS antibodies (1:1000;
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Enzo Life Sciences, Catalogue #ADI-AAP-221-F) overnight at 4°C. After overnight
incubation, blots were washed in TBS-T (137 mM NaCl, 2.7 mM KCl, 19 mM Tris Base,
1 % Tween, pH 7.4) and then probed with goat anti-rabbit IgG antibodies conjugated to
horseradish peroxidase (1:10 000) for 1 h at room temperature. Blots were once again
washed in PBS with 1 % BSA and then treated with a Bio-Rad Clarity Western ECL
substrate kit (Bio-Rad 1705061). Blots were then imaged using the Froggabio camera
system to determine the levels of antibody binding. Following imaging blots were
washed in TBS-T and reprobed with an antibody against the housekeeping protein,
GAPDH (1:5000; Abcam, Catalogue # ab9485), before being reimaged through the same
protocol in order to normalize FAS levels to GAPDH though densitometry using ImageJ
software.

2.5 Statistical Analysis
N values represent separate animal tissue harvests coupled to multiple repetitions
of intra-experimental trials. Collected data was analyzed through Microsoft Excel 2010 to
calculate standard deviation, and generate figures. Raw data was subsequently imported
into GraphPad Prism 5 in order to carry out various statistical analyses depending upon
the number of variables associated with the given experiment. T-tests were utilized
within data collected with only one measured variable, and Two-way ANOVA was
conducted on subject matter concerning 2 variables coupled to bonferonni post-hoc tests.
Significance threshold was set to be α = 0.05, to account for only 5% chance of observing
the given trend by chance alone.
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Chapter 3.

Results

3.1 BMDM culture establishment
The initial focus of this study was to establish the WT and Timp3-/- BMDM
cultures and to characterize these cell lines to ensure responses to stimulation were
similar to previously published studies [72]. Achieving these goals required establishing
cell cultures to support the growth of BMDMs (i.e. L929 cells, a source of M-CSF, which
is required for the differentiation of pluripotent hematopoietic stem cells to BMDMs),
and optimization of culture materials and animal colonies [86]. The goal of culture
establishment was to generate functionally similar BMDMs to those described previously
within the literature [72]. The following results are associated with BMDM culture
establishment and characterization.

3.1.1 BMDM-derived TIMP3 regulates Il12b and Nos2 expression in
M1-polarized macrophages
IL12b and Nos2 are genes associated with the M1-polarized macrophages. In past
studies Timp3-/- BMDMs expressed greater levels of these two genes and similar trends
were expected from our cultured BMDMs [72]. Steady state mRNA levels of the M1
specific genes Il12b and Nos2 were analyzed through qRT-PCR in unpolarized (M0) and
M1-polarized WT and Timp3-/- BMDMs. Expression of Il12b was significantly elevated
in the M1-polarized Timp3-/- BMDMs as compared to M1-polarized WT BMDMs
(Figure 3-1). Furthermore, treatment of Timp3-/- BMDMs with rTIMP3 resulted in a
significant decrease in Il12b expression (Figure 3-1). Il12b mRNA expression in Timp3-/-
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Figure 3-1: BMDM-derived TIMP3 regulates Il12b expression in M1-polarized
macrophages.
Use of qRT-PCR revealed that M1-polarized WT and Timp3-/- BMDMs have
significantly increased Il12b mRNA levels compared to unpolarized BMDMs of a similar
genotype (A). Unpolarized BMDM Il12b expression is not significantly different
between WT and Timp3-/- BMDMs; however, M1-polarized Timp3-/- BMDMs have
significantly increased Il12b mRNA levels compared to WT M1-polarized BMDMs (A;
mean ± SEM, N = 4-6; * indicates P < 0.05 vs. all other experimental groups, # indicates
P < 0.05 vs. all other experimental groups, Two-way ANOVA with post-hoc Bonferroni
correction). Importantly, the elevated Il12b expression in Timp3-/- BMDMs is
significantly reduced following the addition of rTIMP3 for the duration of the polarizing
stimulus (B; mean ± SEM, N = 6; * indicates P < 0.05 vs. WT M1-polarized PBS, #
indicates P < 0.05 vs. Timp3-/- M1-polarized PBS, Two-way ANOVA with post-hoc
Bonferroni correction).
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rTIMP3 treated cells was not significantly different from untreated M1-polarized WT
BMDMs (Figure 3-1). Additionally, expression of Nos2 was significantly elevated in the
M1-polarized Timp3-/- BMDMs vs. M1-polarized WT BMDMs (Figure 3-2). Nos2
expression following rTIMP3 treatment of Timp3-/- BMDMs was not significantly
different from the WT BMDMs or the untreated Timp3-/- BMDMs (Figure 3-2).
Importantly, while treatment of Timp3-/- BMDMs with rTIMP3 did not result in a
significant decrease in Nos2 expression compared to untreated Timp3-/- BMDMs,
expression of Nos2 in rTIMP3-treated Timp3-/- BMDMs was no longer significantly
different vs. WT BMDMs (Figure 3-2) suggesting partial effect of the treatment.

3.1.2 Quantifying metalloproteinase activity in WT and Timp3-/unpolarized and M1-polarized BMDMs
Our characterization of the levels of IL12b and Nos2 showed similar trends to past
publications, allowing us to now expand on previous studies and further characterize
these cells by examining the role of TIMP3 in regulating metalloproteinase activity.
Following 24 h of BMDM culture, elevated metalloproteinase activity in conditioned
media (CM) of Timp3-/- BMDMs was detected (Figure 3-3). The OmniMMP activity
assay was performed over a 48 h time course (Figure 3-3). Data was analysed by area
under the curve (AUC) for each respective polarization and treatment, which allowed for
quantification of total metalloproteinase activity over time. The results from the AUC
analysis show no differences in metalloproteinase activity between WT and Timp3-/unpolarized BMDMs (Figure 3-4). WT M1-polarized BMDMs have reduced
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Figure 3-2: M1-polarized Timp3-/- BMDMs have elevated Nos2 expression
compared to M1-polarized WT BMDMs.
Analysis with qRT-PCR revealed M1-polarized WT and Timp3-/- BMDMs have
significantly increased Nos2 mRNA levels compared to unpolarized BMDMs of a similar
genotype (A). Furthermore, Timp3-/ - M1-polarized BMDMs have significantly elevated
Nos2 expression compared to similarly polarized WT BMDMs (A; mean ± SEM, N = 46, * indicates P < 0.05 vs. all other treatment groups, # indicates P < 0.05 vs. all other
treatment groups, Two-way ANOVA with post-hoc Bonferroni correction). There is no
significant difference in Nos2 expression between M1-polarized Timp3-/- BMDMs treated
with supplemental rTIMP3 and any other treatment group (B; mean ± SEM, N = 6, *
indicates P < 0.05 vs WT M1-polarized PBS, Two-way ANOVA with post-hoc
Bonferroni correction).
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Figure 3-3: Metalloproteinase activity levels in CM of unpolarized and M1polarized WT and Timp3-/- BMDMs
WT and Timp3-/- BMDM metalloproteinase activity, as measured by the
OmniMMP assay. Samples from the CM of unpolarized WT and Timp3-/- BMDMs are
elevated when compared to respective M1-polarized samples. (mean ± SEM, N = 4).
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metalloproteinase activity levels in conditioned media samples when compared to their
WT unpolarized counterparts (Figure 3-4). M1-polarized Timp3-/- BMDMs, however,
have significantly elevated metalloproteinase activity compared to M1-polarized WT
BMDMs (Figure 3-4). The 46 h measurement marked peak metalloproteinase activity
within the 48 h time course. Treatment of M1-polarized WT BMDMs with rTIMP3 did
not appear to affect peak metalloproteinase activity. Supplemental rTIMP3 within culture
media, however, did significantly reduce metalloproteinase activity from M1-polarized
Timp3-/- BMDMs (Figure 3-5). Furthermore, following treatment with rTIMP3, no
differences in metalloproteinase activity were detected between M1-polarized Timp3-/and WT BMDMs (Figure 3-5).

3.2 BMDM apoptosis
Previous studies suggested that TIMP3 appears to have a role in regulating
apoptosis [80]. Thus, our next focus in testing our hypothesis was to test the ability of
Timp3-/- macrophages to undergo apoptosis. Importantly, we utilized three complimentary
methods to detect apoptosis: 1) Caspase activation (FLICA staining); 2) DNA
fragmentation (TUNEL staining); and 3) loss of membrane polarity (Annexin V staining).
These methods were used together to confirm that we were specifically assessing
macrophage apoptosis as it has previously been shown that use of individual markers of
apoptosis, such as caspase activation, yields false positives in some cell types (i.e.
macrophages) [87].
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Figure 3-5: Recombinant TIMP3 treatment reduces peak metalloproteinase activity
in M1-polarized Timp3-/- BMDMs.
M1-polarized Timp3-/- BMDMs in the presence of rTIMP3 have significantly
reduced peak metalloproteinase activity (at the 46 h time point) compared with untreated
Timp3-/-BMDMs. rTIMP3 treated Timp3-/- BMDMs are not significantly different when
compared to WT M1-polarized BMDMs (mean ± SEM, N = 4, # indicates P < 0.05 vs
Timp3-/- PBS treated cells, according to two-way ANOVA with post-hoc Bonferroni
correction).
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3.2.1 Effect of sFASL treatment on caspase activity in unpolarized
BMDMs
As sFASL is a known apoptotic stimulus for macrophages, baseline levels of
unpolarized (M0) BMDM apoptosis were first determined [65]. Unpolarized BMDMs
treated with sFASL for 2, 4 or 8 h showed no significant changes in caspase activity
(Figure 3-6). In fact, caspase activity levels decreased throughout the 8 h stimulation
time course (Figure 3-6). Baseline FLICA measurements revealed that 1 – 2 % of all
unpolarised BMDMs have active caspases regardless of the presence of pro-apoptotic
stimulation. Thus, as this data suggests that unpolarized BMDMs resist sFASL-induced
apoptosis, further apoptosis studies on unpolarized cells were not conducted.

3.2.2 M1-polarized WT BMDMs show induction of caspase activity
following sFASL stimulation
WT M1-polarized BMDMs were stimulated with either PBS or sFASL for 2, 4 or
8 h and stained with FLICA to measure intracellular caspase activity in order to measure
sFASL induced apoptosis. The baseline readings at the 2 h mark showed a relatively high
baseline of caspase activity in the M1-polarized BMDM with no significant differences at
2 h between PBS and sFASL treated WT BMDMs (Figure 3-7). At the 4 h time point,
baseline PBS caspase activity diminished toward levels similar to those seen in the
unpolarized WT BMDMs (Figure 3-6). Furthermore, a significant increase in caspase
activity was detected at the 4 h time point in WT BMDMs treated with sFASL (Figure 37). By 8 h, caspase activity in PBS treated M1-polarized WT BMDMs decreased to very
low levels, though a similar length stimulation of these cells with sFASL did significantly
increase the level of caspase activity (Figure 3-7). Thus, WT M1-polarized BMDMs
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Figure 3-6: WT unpolarized
polarized BMDMs do not elevate caspase activity in response to
sFASL stimulation
Stimulation of WT BMDMs with sFASL did not yield any notable increase in
caspase activity in unpolarized BMDMs.. Measurements were taken at 2, 4 and 8 h of
sFASL stimulation, and
nd no caspase induction occurred at any point along the time course.
By the end of the 8 h stimulation
stimulation, levels of caspase activation had diminished beyond the
2 and 4 h measurements (mean ± SEM, N = 55-8, P = ns, according to t-test
est).

45

Caspase activity
(% cells FLICA positive)

12
10
8
6

*

4

*

2
0
PBS

sFASL

PBS

sFASL

PBS

sFASL

2
4
8
Stimulation length (Hours) and treatment

A

B
Figure 3-7: M1-polarized
polarized WT BMDMs show induction of caspase activity
following sFASL stimulation.
Measurements of FLICA from to 2 - 8 h in WT M1-polarized
polarized BMDMs show
significant induction of caspase activity at 4 and 8 h time points with sFASL treatment.
The amount of caspase activity diminishe
diminished during the 8 h time course,, at the end of
which the signal was minimal (mean ± SEM, N = 5-8, * indicates P < 0.05 vs PBS
treatment, according to t--test). (B) Representative images at the 4 h time point FLICA
stained WT M1-polarized
polarized BMDMs show elevated caspase activity in sFASL treated M1M1
polarized BMDMs.
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demonstrated a response to sFASL by increasing caspase activation, though this activity
was only apparent at the 4 and 8 h time points. Baseline caspase activity measurements
were not significantly different between WT and Timp3-/- BMDMs at 2, 4 or 8 h
following treatment with PBS (Figure 3-8). For these studies, results were normalized to
WT BMDMs for each experiment to display absolute changes between genotypes. As
previously observed in WT BMDMs at baseline (Figure 3-7), the percentage of positive
cells decreased in both genotypes over the course of the 8 h PBS stimulation.

3.2.3 Timp3-/- BMDMs have suppressed sFASL induced caspase
activation compared to WT BMDMs
Stimulation with sFASL was previously shown to induce an increase in M1polarized WT BMDM caspase activity at the 4 and 8 h time points (Figure 3-7).
Repeating those previous experiments with M1-polarized Timp3-/- BMDMs revealed a
marked attenuation in the sFASL-induced caspase activity in M1-polarized Timp3-/BMDMs compared to WT BMDMs (Figure 3-9). At 2 h, there is no significant
difference detected between the WT and Timp3-/- BMDMs (Figure 3-9). However, the
difference between WT and Timp3-/- BMDMs was significant at the 4 h time point
(Figure 3-9). By 8 h post-stimulation, absolute caspase activity levels had decreased in
both WT and Timp3-/- BMDMs with an equivalent level of caspase activity between the
two genotypes. Overall these results support Timp3-/- BMDMs having decreased caspase
activity in response to sFASL compared to WT BMDMs.
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Figure 3-8: Baseline Timp3-/- M1-polarized
polarized BMDM caspase activity is not
significantly different from WT BMDMs.
FLICA assay measurements of M1-polarized WT and Timp3-/- BMDMs treated
with PBS for 2, 4 and 8 h show nno
o significant differences between the two genotypes.
The baseline values depicted in this figure are normalized to M1
M1-polarized
polarized WT PBS
stimulated BMDMs for each experiment to account for day
day-to-day
day variability within
samples (mean ± SEM, N = 55-8, P = ns, according to two-way
way ANOVA with post-hoc
post
Bonferroni correction).
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Figure 3-9: Timp3-/- BMDMs have attenuated sFASL induced caspase activation
compared to WT BMDMs.
FLICA assay measurements on M1
M1-polarized WT and Timp3-/- BMDMs
stimulated with sFASL for 2, 4 and 8 h. A significant decrease in caspase activity was
measured in Timp3-/- BMDMs compared to WT BMDMs with 4 h sFASL stimulation.
stimulation
Data is normalized to M1
M1-polarized
polarized WT sFASL stimulated BMDMs for each experiment
to account for day-to-day
day variability within samples (mean ± SEM, N = 5-8,
5 * indicates P
< 0.05 vs WT cells,, according to t-test).
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3.2.4 TUNEL positivity induced by sFASL in M1-polarized WT
BMDMs
To further test that our caspase findings were reflective of altered apoptosis,
DNA fragmentation in WT BMDMs was assessed following 2, 4, or 8 h of stimulation
with PBS or sFASL by TUNEL staining. While the percentage of TUNEL positive cells
significantly increased at 4 h post-stimulation with sFASL compared to PBS, no
significant differences were detected at any of the other time points examined (Figure 310). Timp3-/- BMDMs had similar baseline (PBS-treated) levels of TUNEL positivity
compared to WT BMDMs with no significant differences observed between genotypes
over the 8 h time course with PBS treatment (Figure 3-11). We next examined TUNEL
staining in WT and Timp3-/- BMDMs stimulated with sFASL to determine if there were
differences in the response to sFASL between WT and Timp3-/- BMDMs. After,
stimulation of 2, 4 or 8 h with sFASL, no significant differences were detected between
WT and Timp3-/- BMDMs in the number of TUNEL positive cells (Figure 3-12). Data
was again normalized to WT BMDMs to control for day-to-day variability in data
collection.

3.2.5 sFASL stimulation induces less Annexin V positivity in Timp3-/BMDMs compared to WT BMDMs
To finalize our analysis of apoptosis, we next assessed the presence of
phosphatidylserine on the cell membrane of BMDMs through the detection of
Fluorescein isothiocyanate (FITC)-labelled Annexin V by flow cytometry. For these
studies, M1-polarized WT BMDMs were stimulated with sFASL for either 1 or 2 h. No
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Figure 3-10: sFASL induces increased TUNEL positivity in WT M1--polarized
BMDMs.
polarized BMDMs were stimulated with either PBS or sFASL for 2, 4 or
WT M1-polarized
8 h. Following stimulation cells were stained with TUNEL reagent to highlight cells
undergoing apoptosis. No significant differences were seen between sFASL and PBS
stimulated cells at 2 or 8 h. There was a significant increase in WT BMDM TUNEL
staining at 4 h following sFASL stimulation, when compared to PBS controls (mean ±
SEM, N = 6, P < 0.05, according to t-test).
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Figure 3-11: PBS-stimulated
stimulated Timp3-/- BMDM TUNEL positivity is not significantly
different from WT BMDMs.
WT and Timp3-/- BMDMs were treated with PBS over the course of 2, 4 and 8 h
and subsequently stained with TUNEL reagent. There were no significant differences
between WT and Timp3-/-/- BMDMs in relation to TUNEL positive cells at any time point
along the time course. Data is relative to the WT PBS stimulated BMDMs so as to
account for any day-to-day
day variability in samples (mean ± SEM, N = 6, P = ns,
ns according
to t-test).

52

TUNEL positive cells (% WT sFASL)

160
140
120
100
80
60
40
20
0
2

4
Stimulation length (Hours)

8

Figure 3-12: sFASL-stimulated
timulated Timp3-/- BMDM TUNEL positivity
sitivity is not
significantly different from WT BMDMs.
WT and Timp3-/- BMDMs were stimulated with sFASL over the course of 2, 4
and 8 h and subsequently stained with TUNEL reagent. There were no significant
differences between WT and Timp3-/- BMDMs in relation
tion to TUNEL positive cells at any
time point along the time course. Data is relative to the WT sFASL stimulated BMDMs
so as to account for any day
day-to-day
day variability in samples (mean ± SEM, N = 6, P = ns,
according to t-test).
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significant differences in Annexin V positivity were detected between PBS and sFASL
stimulated BMDMs after 1h of stimulation (Figure 3-13). However, a significant
increase in the proportion of cells staining positive for Annexin V was observed
following sFASL stimulation for 2 h in WT BMDMs (Figure 3- 13). Thus, based on this
data, the 2 h time point was utilized in subsequent analyses. Similar to our analysis of
caspase activity and DNA fragmentation, no significant differences were detected in
Annexin V staining between WT and Timp3-/- BMDMs following 2 h of stimulation with
PBS (Figure 3-14). This suggests that baseline apoptosis is similar between WT and
Timp3-/- BMDMs. Analysis of Annexin V staining revealed that following treatment with
sFASL for 2 h, however, significantly fewer Timp3-/- BMDMs were Annexin V positive
compared to WT BMDMs (Figure 3-15). Data is represented as a fold change from WT
sFASL treated cells so as to account for variability from day-to-day measurements.
Furthermore, 14% of WT BMDMs were Annexin V positive following sFASL treatment
and 8.4% of the population was non-viable based on propidium iodide staining. Timp3-/BMDMs has significantly less Annexin V positivity (11.6%) with only 6.3% of the
population being non-viable.

3.3 Measurements of BMDM FAS
Following apoptotic assessment of BMDMs, subsequent experiments aimed to
elucidate how this attenuated response was mediated. For these studies, FAS levels, both
the gene expression as well as protein abundance, were analyzed to determine if there
were any baseline differences in FAS between WT and Timp3-/- BMDMs. Second, a
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Figure 3-13: M1-polarized
polarized WT BMDMs show increased Annexin V fluorescence
following sFASL stimulation.
Data depicts flow cytomet
cytometric analysis of WT M1-polarized
polarized BMDMs stained with
FITC-Annexin
Annexin V and PI after 1 and 2 h stimulations with either PBS or sFASL. The data
supports a significant increase in the level of Annexin V+/PI- cells after 2 h of sFASL
stimulation in M1-polarized
polarized WT BMDMs. The data at the 1 h time point is consistent
with this data, though no significant differences were observed
ed (mean ± SEM, N = 3, 10;
* indicates P < 0.05 vs PBS treatment
treatment, according to t-test).
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Figure 3-14: PBS stimulation of WT and Timp3-/- BMDMs yields no significant
difference in Annexin V positivity.
Data depicts flow cytometric analysis of WT and Timp3-/- M1-polarized
polarized BMDMs
(Annexin V+/PI-) after 2 h of PBS stimulation.. No significant differences were found
(mean ± SEM, N = 10; P = ns, according to t-test).
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Figure 3-15: M1-polarized
polarized Timp3-/- BMDMs have less Annexin V positivity following
sFASL stimulation.
cytometric analysis for proportion of Annexin V+/PI- WT and
Data depicts flow cytometr
Timp3-/- M1-polarized
polarized BMDMs following 2 h of sFASL stimulation. Compared to WT
BMDMs, there is a significant reduction in the percentage of Annexin V positive Timp3-/BMDMs (mean ± SEM, N = 10; P < 0.05, according to t-test).
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rescue study utilizing rTIMP3 to enhance metalloproteinase inhibition and increase the
response to sFASL in Timp3-/- BMDMs was performed.

3.3.1 Assessing Fas mRNA levels and FAS protein abundance in
unpolarized and M1-polarized WT BMDMs
Microarray data of WT unpolarized (M0) and M1-polarized BMDMs from a
previous study was mined to examine steady state levels of mRNA encoding Fas [72].
Analysis of the microarray data revealed that Fas expression in M1-polarized WT
BMDMs was significantly elevated compared to expression in unpolarized cells (Figure
3-16). Lower expression of Fas in the unpolarized BMDMs is consistent with our earlier
data demonstrating that caspase activity was unchanged in unpolarized BMDMs in
response to sFASL stimulation (Figure 3-6). Western blotting with antibodies against
FAS was used to assess FAS abundance in the cell lysate from unpolarized and M1polarized WT BMDMs with no significant differences detected (Figure 3-17). Data are
represented as the relative abundance of FAS (normalized to GAPDH) as a percentage of
the WT unpolarized BMDM FAS levels.

3.3.2 Measuring Fas mRNA levels and FAS protein abundance
differences in WT and Timp3-/- BMDMs
Comparisons of steady state mRNA levels as measured by microarray analysis of
WT and Timp3-/- M1-polarized BMDMs was further mined to determine the steady state
levels of Fas mRNA [72]. Expression of Fas by M1-polarized Timp3-/- BMDMs was not
significantly different from the expression observed in M1-polarized WT BMDMs
(Figure 3-18). Western blot analysis for levels of FAS in cell lysate from M1-polarized

58

4

***

Fas (Fold Change M0)

3.5
3
2.5
2
1.5
1
0.5
0
M0

M1
Polarization

Figure 3-16: WT M1-polarized BMDMs have increased Fas expression.
These data were mined from previous microarray analysis of unpolarized (M0)
and M1-polarized BMDMs [72]. Data is expressed as fold change in Fas expression from
WT unpolarized BMDMs. Levels of Fas mRNA are significantly elevated in M1polarized BMDMs as compared unpolarized BMDMs (mean ± SEM, N = 4; ***
indicates P < 0.001, according to t-test).
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Figure 3-17:: FAS protein abundance is not significantly different between WT
unpolarized and M1-polarized
polarized BMDMs.
This figure depicts w
western
estern blot data for FAS protein abundance in unpolarized
and M1-polarized
polarized BMDMs
BMDMs. (A) No significant differences are observed between
unpolarized and M1-polarized
polarized WT BMDMss in terms of FAS protein levels in lysates.
FAS abundance was normalized to GAPDH for each lane. (mean ± SEM, N = 4; P = ns,
according to t-test). (B)) Representative image of the western blot data
data.
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Figure 3-18: Steady state Fas mRNA levels are not significantly different between
WT and Timp3-/- M1-polarized BMDMs.
This data mined from microarray analysis of WT and Timp3-/- M1-polarized
BMDMs represents the level of steady state Fas mRNA. Data is expressed as Fas
expression relative to WT M1-polarized BMDMs. Levels of Fas mRNA are not
significantly different between genotypes (mean ± SEM, N = 4; P = ns, according to ttest).
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WT and Timp3-/- BMDMs revealed no significant differences between WT and Timp3-/M1-polarized FAS protein levels densitometric analysis (Figure 3-19). Data are
represented as a relative abundance of FAS (after normalization to GAPDH) as a
percentage of the WT M1-polarized lysate FAS levels.

3.3.3 rTIMP3 rescues reduced caspase activity in M1-polarized
Timp3-/- BMDMs following sFASL stimulation
WT and Timp3-/- BMDMs were treated with rTIMP3 to determine if the loss of
TIMP3 was responsible for reduced sFASL-induced apoptosis in Timp3-/- BMDMs.
BMDMs were stimulated with sFASL or PBS over the course of 2 h in the presence of
rTIMP3. Control treated Timp3-/- BMDMs stimulated with sFASL had significantly lower
caspase activity compared to sFASL-stimulated WT BMDMs (Figure 3- 20). Caspase
activity in Timp3-/- BMDMs treated with rTIMP3, however, was not significantly
different compared to similarily treated WT BMDMs (Figure 3-20).
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Figure 3-19: There are no significant differences between WT and Timp3-/- M1polarized BMDM FAS protein levels.

M1-polarized WT and Timp3-/- BMDM cell lysates probed for FAS protein
content. (A) Analysis of w
western blots for FAS protein content (normalized to GAPDH)
in BMDM lysate shows no significant differences between genotypes (m
mean ± SEM, N =
6, 5; P = 0.0854, t-test).. ((B) Representative image of the western blot data.
data
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Figure 3-20: rTIMP3 rescues depressed caspase activity in M1-polarized Timp3-/BMDMs following sFASL stimulation.
Data depicting caspase activity following treatment with rTIMP3 or DMSO
control, coupled to 2 h stimulation with either PBS or sFASL. Treatment with rTIMP3
during the 2 h sFASL stimulation abolishes the difference between WT and Timp3-/BMDM caspase activity levels. Timp3-/- M1-polarized BMDMs have significantly
increased caspase activity levels following rTIMP3 and sFASL treatments when
compared to all other Timp3-/- BMDM treatment groups (P < 0.05, N = 6). rTIMP3
treated Timp3-/- M1-polarized BMDMs stimulated with sFASL are not significantly
different from the similarly treated WT BMDMs (mean ± SEM, N = 6, * indicates P <
0.05 vs. all other Timp3-/- treatments, ## indicates P < 0.01 vs. WT with same treatment,
according to multiple 2-way ANOVA analyses with post-hoc Bonferroni tests).
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Chapter 4.

Discussion

4.1 Summary of findings
Macrophages have been found to both promote and resolve inflammation in
ARDS; however, the mechanisms controlling the ability of macrophages to mediate these
different functions remain to be determined [9]. The focus of our study was to examine a
potential mechanism enabling TIMP3 to promote apoptosis of murine macrophages. The
suggested model proposes that in the absence of TIMP3 decreased metalloproteinase
inhibition will result in the stabilization of FAS on the cell surface, and ultimately
promote apoptosis.
My first objective was to establish and characterize WT and Timp3-/- BMDM
cultures. Previous studies revealed that Timp3-/- BMDMs express elevated levels of proinflammatory genes in response to LPS treatment compared to WT BMDMs [72]. Our
initial studies established all of the techniques and cultures required to generate BMDMs.
Furthermore, characterization of WT and Timp3-/- BMDMs revealed similar differences
in gene expression as previously observed [72]. Futhermore, we show for the first time
that Timp3-/- BMDMs have greater metalloproteinase activity compared to WT BMDMs,
and the resultant increases in metalloproteinase activity were rescued by treatment with
rTIMP3.
The second objective of my study was to identify the mechanism through which
TIMP3 regulates macrophage apoptosis. Timp3-/- BMDMs had reduced levels of
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apoptosis in response to sFASL as assessed by FLICA (caspase activity) and Annexin V
staining. Additionally, the resistance to sFASL-induced apoptosis in Timp3-/- BMDMs
was rescued by treatment with rTIMP3. Lastly, assessment of FAS mRNA and protein
levels revealed no significant differences between WT and Timp3-/- BMDMs.
I have shown that BMDMs lacking TIMP3 have increased expression of proinflammatory genes following stimulation with LPS, and thereby could promote a more
pro-inflammatory milieu within their local microenvironment (Figure 3-1 and 3-2). If
these inflammatory macrophages lacking TIMP3, which promote inflammatory signals
above similarly activated WT macrophages, were to resist pro-apoptotic signals they
would persist, and possibly generate a chronic, non-resolving inflammation within the
lung.

4.2 Contributions of research to current state of knowledge
4.2.1 Macrophage Polarization and Metalloproteinase Activity
The first objective of this thesis was to establish BMDM culture method and to
confirm the role of TIMP3 in the regulation of macrophage polarization and
metalloproteinase activity. BMDMs were utilized within this thesis as a substitute cell
type for recruited alveolar macrophages. Use of BMDMs has one major advantage over
alveolar macrophages; materials harvested from one animal can produce approximately
200 fold the number of macrophages that can be extracted from the lungs of a mouse.
This greatly increased yield of macrophages enables the use of multiple concurrent
techniques that require large numbers of cells, and allows those techniques to utilize cells

66

from the same animal. However, the major issue of utilizing BMDMs is the lack of
physiological translation as to what a BMDM represents in a living system [88]. BMDMs
are a cell culture generated macrophage, and as such direct comparisons to tissue
macrophages, specifically alveolar macrophages, are difficult. Previous works from the
Center for Lung Biology (University of Washington, Seattle, Washington) had
demonstrated that Timp3-/- BMDMs had increased expression of genes associated with
M1-polarization compared to WT BMDMs following LPS stimulation [72]. We were
able to reproduce elevated IL12b and Nos2 expression in Timp3-/- BMDMs and confirm
the importance of macrophage-derived TIMP3 to pro-inflammatory gene expression.
Macrophages, have been found to differentially express multiple
metalloproteinases and TIMPs depending on macrophage polarization [58]. Furthermore,
metalloproteinases have been shown to govern macrophage recruitment and function
suggesting that the control of their activity is essential during the acute phase of
inflammation [61, 63]. Interestingly, the specific role of metalloproteinase activity in
macrophage polarization has not been addressed. In order to characterize the role of
metalloproteinases in macrophage polarization, as well as the role of macrophage-derived
TIMP3 in the inhibition of metalloproteinases, WT and Timp3-/- BMDMs were assessed
for metalloproteinase activity. Total metalloproteinase activity was significantly
decreased in the conditioned media from M1-polarized WT BMDMs compared to
unpolarized WT BMDMs (Figure 3-4). Furthermore, M1-polarized Timp3-/macrophages were found to have significantly increased metalloproteinase activity vs.
M1-polarized WT BMDMs, which was rescued by the addition of rTIMP3 (Figure 3-4
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and 3-5). Previous work found that Timp3 expression increases when BMDMs are M1polarized, compared to unpolarized, suggesting a role for TIMP3 in the M1-polarized
macrophage [72]. My data supports this finding by highlighting the importance of
macrophage-derived TIMP3 as an inhibitor for metalloproteinases in the M1-polarized
BMDM.
While TIMP3 is primarily thought to function as an inhibitor of
metalloproteinases, it has been shown to have metalloproteinase independent functions.
For example, TIMP3 has been shown to inhibit angiogenesis by binding to vascular
endothelial growth factor receptor (VEGFR) and blocking VEGF/VEGFR2 interaction
[89, 90]. Macrophage-derived TIMP3 has been previously found to regulate macrophage
polarization; however, the mechanism through which TIMP3 regulates this process is
unknown [72]. With our data suggesting that Timp3-/- BMDMs have increased
metalloproteinase activity and that treatment with rTIMP3 rescues this effect, we can
conclude that TIMP3 likely regulates macrophage polarization through the inhibition of
metalloproteinase activity, and that TIMP3 reduces extracellular metalloproteinase
activity in BMDMs.

4.2.2 Macrophage Apoptosis
Pro-inflammatory macrophages that are resistant to apoptotic stimuli could be
responsible for persistent inflammation following ARDS [88]. Regarding BMDMs, the
unpolarized BMDM most closely represents in vivo naive tissue-macrophages within
their target tissue; this is based on their differentiation into macrophages following M-
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CSF stimulation coupled the lack of polarizing stimulus present in their surrounding
environment [91]. Hence, we initially examined apoptosis within unpolarized BMDMs to
determine the baseline levels of responsiveness to apoptotic stimuli within macrophages.
FLICA assessment showed no differences in caspase activity levels between unpolarized
BMDMs stimulated with sFASL or PBS, which suggests that unpolarized macrophages
are resistant to sFASL-mediated apoptosis. The finding that naïve macrophages do not
respond to sFASL suggests they resist apoptotic clearance from the site of injury,
allowing first for their polarization in order to carry out immunomodulatory effects. The
ability for unpolarized macrophages to resist apoptosis would aid in the pro-inflammatory
or anti-inflammatory process, as dictated by the local tissue microenvironment, and the
various signaling molecules there-in [29].
Macrophages, specifically M1-polarized macrophages, are one of the primary
mediators of inflammation during ARDS [17]. The method of macrophage clearance
from the inflamed tissue (e.g. apoptosis and phagocytosis vs. migration to lymph nodes),
however, remains the focus of some debate [92, 93]. Recent work in a model of
peritoneal inflammation, however, revealed that apoptosis and phagocytosis might be the
primary means of macrophage clearance from inflamed tissues [19]. While this evidence
is within peritoneal tissue, it still alludes to mechanisms that are carried out in vivo and
may reflect the processes within the lungs. Our data suggests that M1-polarized BMDMs
are susceptible to sFASL-induced apoptosis, which supports the concept that apoptosis
may be a key mechanism mediating the specific clearance of pro-inflammatory
macrophages. Furthermore, the susceptibility of M1-polarized (and not unpolarized)
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macrophages to sFASL-induced apoptosis would allow for clearance of apoptotic proinflammatory macrophages, likely mediated through activation of death-receptors from
external signaling molecules (i.e. sFASL), while at the same time allowing for protection
of incoming naïve macrophages that could promote recovery from injury [19, 65, 72].
Resistance to sFASL-induced apoptosis (i.e. in the absence of TIMP3) would potentially
restrict clearance of pro-inflammatory macrophages thereby limiting resolution of
inflammation. Importantly, these findings support the works cited as rationale, which
show hindered recovery of Timp3-/- lung inflammation by BAL fluid analysis showing
greater inflammatory cell presence and decreased markers of inflammatory resolution vs.
WT mice [72, 75].
Macrophage apoptosis is mediated by proteins such as TNFα and sFASL;
however, resident and recruited macrophages appear to have different susceptibility to
these proteins [92, 94–96]. Following bleomycin injury in the lung, resident macrophages
have been found to undergo apoptosis in response to TNFα [94]. Alternatively, work by
Janssen and colleagues found that specifically recruited macrophages possess high levels
of Fas expression following lung injury, and that the majority of these recruited
macrophages were cleared in vivo through apoptosis and phagocytic clearance [92].
Within the same study, use of FAS-blocking antibodies, which blocked FAS activation,
resulted in decreased macrophage clearance following injury [92]. Our finding that
sFASL stimulates apoptosis in M1-polarized macrophages and that Timp3-/- BMDMs are
resistant to sFASL-induced apoptosis demonstrate that TIMP3 is a potential mediator of
FAS-induced apoptosis in macrophages. Additionally, in Timp3-/- mouse lungs with
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reduced clearance of macrophages based on sFASL resistance, the inherent greater M1polarization in those macrophages could exacerbate inflammatory complications present
within ARDS, thus further supporting the proposed model within this study.
Previous publications have shown that apoptosis can be mediated by TIMP3,
specifically by the N-terminus of TIMP3 [80–82, 97]. For example, overexpression of
TIMP3 in a number of cell types leads to increased apoptosis primarily through
stabilization of the death receptor on the cell surface and increased receptor activation
[80–82]. Interestingly, while studies have found that the ability of TIMP3 to promote
apoptosis is dependent on the inhibition of metalloproteinase activity [81, 83, 98], a
recent study found that overexpression of TIMP3 in endothelial cells promotes apoptosis
through a metalloproteinase-independent mechanism [97]. In this study, we have shown
that in the absence of TIMP3, macrophages are resistant to sFASL-induced apoptosis and
this resistance is associated with increased metalloproteinase activity, which provides
strong support for previous studies on TIMP3 regulation of apoptosis. Furthermore, we
found that treatment of Timp3-/- BMDMs with rTIMP3, which decreased
metalloproteinase activity, rescued the observed resistance to apoptosis. Therefore, from
our data we conclude that TIMP3 mediates BMDM apoptosis through inhibition of
metalloproteinase activity.

4.2.3 Regulation of FAS-sFASL Mediated Apoptosis
FAS interaction with sFASL leads to trimerization of the receptor-ligand
complex, recruitment FADD, activation of caspase 8 and ultimately, apoptosis (Figure 1-
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1) [37–39]. The final goal of these studies was to elucidate a possible mechanism
regulating M1-polarized macrophage resistance to sFASL mediated apoptosis. These
experiments were based on the original proposed mechanistic model, in which excessive
metalloproteinase activity leads to excessive processing of FAS and subsequently, a loss
of FAS activation (Figure 1-2). Our finding that Timp3-/- BMDMs are resistant to
apoptosis and that this resistance is associated with increased metalloproteinase activity,
as well as decreased caspase activity, which is downstream of FAS activation, supports
our proposed model (Figures 3-4 and 3-9). However, our specific analyses of FAS levels
within the unpolarized and M1-polarized WT and Timp3-/- BMDMs examining
alterations to FAS levels did not support our hypothesis.
The ability of FAS to induce macrophage apoptosis appears to be limited to
specific subsets of macrophages. In a model of LPS-induced lung infection, recruited
macrophages, and not resident macrophages, were found to express high levels of FAS
and undergo apoptosis in response to FAS-activating antibodies [92]. Additionally, a
study by Park and colleagues showed in vitro analysis of human monocyte and
macrophage FAS mediated apoptosis and discovered that monocytes but not
macrophages underwent apoptosis when stimulated with FAS [99]. Importantly, the
previous study utilized non-polarized monocyte-derived macrophages (i.e. unpolarized
macrophages) [99]. Our data that Fas expression is increased in M1-polarized murine
BMDMs and that only M1-polarized BMDMs appear to be susceptible to FAS-induced
apoptosis supports these previous studies.
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TIMP3 has previously been found to stabilize FAS on the cell surface, thereby
promoting apoptosis [67, 81]. Furthermore, ADAM17, which is inhibited primarily by
TIMP3, is known to cleave multiple members of the TNFR superfamily, including FAS
[50, 100]. We found that in the absence of TIMP3, M1-polarized BMDMs were resistant
to undergoing apoptosis in response to sFASL. Comparison of Fas expression between
WT and Timp3-/- BMDMs revealed similar levels of expression between genotypes
(Figure 3-18) suggesting that the differential response to sFASL was likely due to
translational or post-translational mechanisms (i.e. shedding). Though protein levels of
FAS within Timp3-/- BMDMs were decreased compared to WT BMDMs, these
differences did not reach significance (P = 0.0854; Figure 3-19). The lack of a significant
decrease in FAS suggests that in macrophages, the ability of TIMP3 to regulate FASinduced apoptosis is not due to inhibition of FAS shedding. However, it is important to
note that apoptosis in response to sFASL/FAS interaction requires trimerization of the
ligand/receptor complexes. MMP7 has been found to cleave FAS at the N-terminus
releasing a short peptide (<10kDa) and loss of this peptide impairs trimerization leading
to decreased activation [101]. Furthermore, MMP7 activity has been found to be
increased in mice lacking TIMP3 [77]. Hence, it is plausible that increased MMP7
activity in the absence of TIMP3 may lead to altered processing of FAS and decreased
FAS activation in the absence of significantly altered FAS levels on a western blot.
Alternatively, alterations to sFASL may have mediated some of the observed survival
effects present in the Timp3-/- BMDMs. In addition to FAS processing, MMP7 has also
been shown to cleave sFASL, which is associated with increased cell survival [102].
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Thus, increased metalloproteinase activity in the conditioned media of Timp3-/- BMDMs
may have resulted in increased cleavage of the sFASL and the generation of altered
sFASL that is ineffective in binding or signaling FAS, which would further restrict
apoptosis. This could also account for Timp3-/- BMDMs being resistant to FAS-induced
apoptosis in the absence of detectable differences in overall FAS abundance; however,
this possibility was not examined in the current study.

4.3 Limitations and future directions
4.3.1 Study limitations
In order to assess BMDM apoptosis three separate techniques were utilized.
Technical difficulties arose within each method and the final conclusions drawn were not
supported by TUNEL results. TUNEL, which by definition labels nick ends of the DNA
during the fragmentation process, has also been shown to be non-specific for apoptosis as
it can also stain nuclei in cells undergoing necrotic and autolytic forms of death [103].
Furthermore, TUNEL is a late stage marker of apoptosis, at which point many cell
surface associated efferocytosis targets will be present on the apoptotic cells promoting
its clearance by neighboring phagocytic cells [32]. This potential clearance of
neighboring apoptotic macrophages may have accounted for why we did not observe a
strong induction of TUNEL staining in response to sFASL. Therefore, TUNEL staining
within a homogeneous population of macrophages may not be the best indicator of
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apoptosis. Additionally, TUNEL staining protocols required us to grow BMDMs on glass
coverslips. This meant altering culture conditions by growing our BMDMs on untreated
glass. Analysis of the numbers of BMDMs in a given field of view when cultured on
glass compared with tissue culture plastic suggested that culture on glass resulted in
decreased BMDMs per field of view.
FLICA analysis utilizes a fluorescent marker that binds to active intracellular
caspases in order to highlight cells with internal caspase activity. Caspases, though
generally associated with apoptosis, do not solely function as apoptotic markers, and thus
not all cells positive for caspase activity are apoptotic [104]. Caspases have been known
to become active for multiple different cellular processes including: cell proliferation
[105], differentiation [106], and cell cycle regulation [107]. With this in mind FLICA
positive cells are not assuredly undergoing apoptotic processes, and thus further analyses
were conducted to reinforce the results.
The last maker of apoptosis was assessment of Annexin V/PI staining by flow
cytometry. The majority of difficulties in this technique were associated with obtaining
cells following stimulation. Following M1-polarization BMDMs adhere further to plastic
culture plates, methods requireing mechanical lifting of cells are known to cause
disruption of cell membranes that result in false positives for apoptosis [108]. Thus in
order to safely lift the cells 37°C 0.5 mM EDTA/PBS was utilized. The lifting of the
cells, coupled to the need for live and unfixed cells in annexin V staining may have
altered outcomes compared to the other two fixed, and still plated, methods of apoptotic
measurements.
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Finally, western blotting for FAS utilizing cell lysate samples was not specific to
shed FAS, or to cell-surface FAS. To remedy this shortcoming we attempted preliminary
studies probing conditioned media samples for FAS, however analysis revealed nonspecific smears over the region of the expected bands. A more direct technique to
measure surface FAS such as flow cytometry could be used in the future to test this
possibility.

4.3.2 Future directions
Inflammation following ARDS is a difficult topic, as there are many factors in
involved in the induction and resolution of this complex syndrome. Our data, which
found that TIMP3 potentially mediates clearance of pro-inflammatory macrophages,
focused on only one possible mechanism involved in prolonging the inflammatory
environment within the lungs following injury. One shortcoming of this study was the
sole utilization of sFASL. Future studies should include other TNF superfamily ligands,
such as TNFα in order to fully understand how apoptotic signaling is altered in a variety
of pathways. Coupled to these studies, the identification of specific metalloproteinases
actively involved in shedding events could be ascertained with an immunoprecipitation
assay targeting TIMP3 and ADAM17 or even MMP7 in WT BMDMs to determine if
TIMP3 is regulating ADAM17 or MMP7 activity and thereby, restricting shedding or
cleavage of the proposed targets.
With the completion of these preliminary studies on BMDMs, future key
experiments can be conducted on alveolar macrophages to better understand whether our
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proposed model of macrophage persistence represents the in vivo situation accurately. In
order to support this concept, in vivo experiments are needed. These studies would
involve use of a model of ARDS in WT and Timp3-/- mice (i.e. intratracheal instillation of
LPS), and subsequently treating the mice with rTIMP3 to rescue the impaired resolution
of lung inflammation previously observed in Timp3-/- mice [75]. Macrophages could then
be isolated from the lungs at different timepoints following injury and could be examined
by flow cytometry for markers of apoptosis. Additional markers could be used to
examine macrophage polarization in vivo.

4.4 Summary and conclusions
We have shown support for a model that proposes TIMP3 regulating
inflammatory cell apoptosis in order to control the level of inflammation present at any
given time along tissue repair processes. In the absence of Timp3, M1-polarized
macrophages have increased metalloproteinase activity, are resistant to typical apoptotic
stimuli promoting their longevity, and maintain greater pro-inflammatory gene
expression. Importantly, we have rescued each of these phenotypes by rTIMP3 treatment,
suggesting that rTIMP3 may be a potential therapeutic treatment. These findings further
suggest persistent inflammation following an initial injury within the lung may be due to
lack of clearance (via apoptosis) of pro-inflammatory macrophages. These findings also
suggest that a cell specific target (i.e. macrophage specific) could alleviate the persistent
inflammation in order to aid patients and allow for a more rapid resolution of
inflammation following ALI.
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Major in vivo studies, however, must be conducted before conclusions can be
drawn regarding the application of findings within this thesis to the in vivo setting. In
vitro experiments are much less complex as they utilize a highly selected population of
cells, standardized culture environment, and the ability to directly visualize the cells of
interest. The current study, however, has begun to provide a greater understanding of a
complex problem (i.e. persistent inflammation following ARDS). It is possible that
rTIMP3 could aid in the resolution of inflammation with ARDS; though it’s clear that
more research is needed before definite in vivo and human conclusions can be drawn.
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